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Abstract
Immune dysregulation in HIV-1 infection is associated with increased expression of inhibitory molecules such as CTLA-4,
TGF-b, and IL-10. In this study we examined one potential mechanism for regulating TGF-b and IL-10 expression by HIV-
specific suppressor CD8+ T cells. No overlap between TGF-b, IL-10, and IFN-c cytokine production by HIV-specific CD8+ T
cells was observed. TGF-b positive and IL-10 positive cells were FOXP3 negative, CD25 negative, and displayed a
heterogeneous surface expression of CD127. TGF-b and IL-10 positive CD8+ T cells did not express CTLA-4. Nevertheless,
CTLA-4 blockade resulted in a significant decrease in HIV-specific TGF-b positive and IL-10 positive CD8+ T cell responses,
and a concomitant increase in HIV-specific IFN-c positive CD8+ T cell responses. Depletion of CD4+ T cells abrogated the
impact of CTLA-4 on HIV-specific TGF-b positive and IL-10 positive CD8+ T cells. Our study suggests that CTLA-4 Signaling
on CD4+ T cells regulates the inhibitory functions of the HIV-specific suppressor CD8+ T cells.
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Introduction
Suppressor CD8+ T cells (CD8+ Ts) exert their inhibitory
effects on T cell proliferation and cytokine production through a
cell-cell contact-dependent mechanism [1–4], and by secreting the
immunosuppressive cytokines interleukin-10 and TGF-b [5,6].
CD8+ Ts mediate non-antigen specific suppression of T cell
responses via IL-10 [7–10]. These suppressor CD8+ T cells are
typically CD28 negative [11,12] and express CD25, FOXP3, and
CTLA-4 [1,4,13,14]. Transforming growth factor b (TGF-b)i s
another immunosuppressive cytokine that inhibits T cell functions
[15–18]. TGF-b up-regulates CTLA-4 expression [19–21] and
suppresses T cell proliferation and IL-2 production [22]. Increased
TGF-b and IL-10 is associated with disease progression in HIV-1-
infected patients [23,24], and likely influences the antiviral
immune responses [23–25].
Cytotoxic T lymphocyte antigen 4 (CTLA-4) is overexpressed
on activated T cells and inhibits IL-2 production and cell cycle
progression by binding to its ligands B7-1 (CD80) and B7-2
(CD86) [26,27]. CTLA-4 is also constitutively expressed on
regulatory CD4+ T cells (Treg) and mediates T cell suppression
[27]. Treg inhibits T cells via direct cell-cell interaction or
indirectly by an antigen-presenting cell–mediated mechanism
[28]. High CTLA-4 expression correlates with markers of HIV
disease progression [29–31]. CTLA-4 is upregulated on HIV-
specific CD4+, but not CD8+, T cells and in vitro blockade of
CTLA-4 augments HIV-specific CD4+ T cell functions [29].
Upregulation of CTLA-4 also increases CCR5 expression and
enhances susceptibility of CD4+ T cells to HIV infection [32]. The
frequency of CTLA-4 positive Treg is increased in patients with
chronic HIV-1 infection and is suspected to play a critical
immunomodulatory role leading HIV-associated immune dys-
function [33]. In this study, we explore the relationship between
CTLA-4 positive CD4+ T cells and the production of TGF-b and
IL-10 by HIV-specific CD8+ T cells.
Materials and Methods
Study Subjects and Samples
HIV positive volunteers (n=37) were recruited from the ‘‘The
Research in Access to Care in the Homeless (REACH)’’ cohort in
San Francisco as previously described [2,34]. Demographic
information and CD4+ T cell count was obtained at the time of
enrollment and blood draw. Institutional Review Board approvals
were obtained from the California Department of Public Health
and UCSF Committee on Human Research, and all study
participants gave written informed consent. None of the study
participants have received antiretroviral therapy (ART) for at least
6 months. HIV RNA level was determined from plasma using the
Roche Amplicor 1.5 (Roche, Branchburg, New Jersey), as per
manufacturer’s recommendations. Peripheral blood mononuclear
cells (PBMC) were separated and cryopreserved in liquid nitrogen
until assay time.
Antigens
Peptides corresponding to the clade B consensus sequences of
HIV-1 for Gag and Nef were synthesized as 15 amino acids (a.a.)
overlapping by 11 a.a. (Mitochor Mimotopes,Victoria, Australia).
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8194Synthetic peptides for Gag (total =123), and Nef (total =49), used
for all T cell assays were pooled into one single pool of peptides
with final concentration of 1 mg/ml per peptide [35].
Flow-Based Intracellular Cytokine Staining
Detection of HIV-specific TGF-b, IL-10, and IFN-c production
was performed as previously described [36]. PBMC (1610
6) were
incubated with Gag or Nef peptide pools for 2 hours at 37uCi n
5% CO2 in the presence of one of these following antibodies: anti-
TGF-b RI I( 2mg/ml, R&D systems, Minneapolis MN), anti-
CTLA-4 (5 mg/ml, BD Phamingen), or the respective isotype
control for 12–14 hours at 37uCi n5 %C O 2 in the presence of co-
stimulatory anti-CD49d (1 mg/ml, Becton-Dickinson) and Golgi
stop (BD Pharmigen). Phorbol myristate acetate (PMA, 50 ng/ml)
and ionomycin (1 mg/ml; Sigma-Aldrich, St. Louis, MO),
Lypopolysacccharide (LPS, 1 ng/ml; Sigma-Aldrich), and phyto-
haemagglutinin (PHA, 10 mg/ml; Sigma-Aldrich) were used as
positive controls for TGF-b, IL-10 and IFN-c production
respectively. Media alone without antigen stimulation was used
as negative control. All samples were stained with an amine
reactive viability dye as a dead cell exclusion marker (Molecular
probes, Eugene, OR) [37]. In some experiments depletion of
CD4+ T cells was performed using the MACS CD4 depletion kit
following the manufacturer’s protocol (Miltenyi Biotec, Germany).
Cells were then stained with specific combinations of the following
antibodies: CD27 FITC, CD4 PerCP CY5.5, CD127 Alexa Fluor
647, CD8 PE CY7, CD3 AmCyan (BD Pharmigen). PBMC were
permeabilized and stained with different combinations of the
following antibodies: CTLA-4 APC, IL-10 PE, IL-10 APC, IFN-c
FITC (BD Pharmigen), TGFb PE (Biotest Diagnostics, Denville,
NJ), and analyzed by flow cytometry. A minimum of 30,000 CD3+
T cells per sample were acquired using a 6-color flow cytometer
(LSRII, BD Biosciences) and analysis was performed by FLOWJO
software (TreeStar, San Carlos, CA). Results were expressed as:
Percent TGF-b, IL-10, or IFN-c positive CD8+, T cells (Percent
positive = % antigen-specific - % negative control). Responses
greater than or equal to 0.1% and 2 times the background were
considered positive. The extent of CTLA-4, CD27, and CD127
expression was also assessed. All volunteers demonstrated
significant TGF-b, IL-10, and IFN-c production following
PMA/Ionomycin, LPS, and PHA stimulation respectively.
Background expression was ,0.1 percent.
Flow-Based FOXP3 Staining Assay
PBMC were stained for FOXP3 expression following the
manufacturer’s protocol (eBioscience, San Diego, CA) with some
modifications [2]. Briefly, PBMC (1610
6) were incubated with
HIV peptide pools for 12–14 hrs as described above for
intracellular cytokine staining. Cells were then stained with an
amine reactive viability dye as a dead cell exclusion marker
(Molecular probes) [37], and the following antibodies: FOXP3
FITC (eBioscience), TGF-b PE, CD4 PerCP Cy5.5, CD8 PE
CY7, CD25 allophycocyanin, and CD3 AmCyan (BD Pharmi-
gen). Analysis was performed by flow cytometry as described
above. The percentage of TGF-b positive CD8+ T cells was
determined and the extent of FOXP3 and CD25 expression was
also assessed. Results were expressed as the fraction of TGF-b
positive cells that expressed FOXP3 or CD25 over the total
number of TGF-b positive cells (equivalent to 100%).
Statistical Analysis
Groups were compared using the Mann-Whitney U test or the
paired t test. Analysis was performed with PRISM software version
4.02 (Graph-Pad). Statistical significance was defined as p,0.05.
Results
TGF-b, IL-10, and IFN-c Producing HIV-Specific CD8+ T
Cells Are Distinct Populations
Specific populations of HIV-specific CD8+ T cells have been
shown to express high TGF-b and IL-10 levels [18,25,38]. We first
measured the frequency of Gag and Nef-specific TGF-b positive
and IL-10 positive CD8+ T cells in 37 HIV-1 infected volunteers
(Fig. 1A). IFN-c production by Gag- and Nef-specific CD8+ T
cells was determined concurrently. Volunteers had a median age
of 45 years (range, 31–61), CD4+ T cell count of 168 cells/mm
3
(range, 19–233), and median HIV plasma RNA of 132200 copies/
ml (range, 19000–780000). Representative plots of the frequency
of the HIV-specific TGF-b positive, IL-10 positive, and IFN-c
positive CD8+ T cells are shown in Fig. 1B. No overlap between
HIV-specific CD8+ T cells producing TGF-b, IL-10 or IFN-c was
observed. All volunteers demonstrated significant Gag- (median
=0.48%; range =0.1%23.5%) and Nef- (median =0.4%; range
=0.1%22.2%) specific IFN-c positive CD8+ T cell responses.
Fourteen and fifteen volunteers demonstrated significant Gag-, and
Nef-, specific TGF-b positive CD8+ T cell responses respectively
(median =0.6%; range =0.15%22.0%, and median =0.4%;
range =0.1%22.0% for Gag and Nef, respectively). Sixteen
volunteers demonstrated significant Gag- (median =0.13%; range
=0.1%20.45%)andNef- (median =0.19%;range =0.1%20.6%)
specific IL-10 positive CD8+ T cell responses. Differences in the
frequencies of Gag- and Nef-specific TGF-b (or IL-10) positive
CD8+ T cell responses was not significant (p=0.22 and p=0.45 for
TGF-b and IL-10 respectively). We have previously demonstrated
that HIV-specific IL-10 positive CD8+ T cells are increased in
advanced HIV disease and are positively correlated with plasma
HIV RNA [38]. No correlation was found between the frequency of
the HIV-specific TGF-b positive CD8+ T cells and the CD4 count
or plasma HIV RNA (for Gag: p=0.07 and p=0.1, for Nef:
p=0.68 and p=0.13, for CD4 count or plasma HIV RNA
respectively; data not shown). However, the relatively small number
of volunteers in the study limited the full examination of this
relationship.
TGF-b Receptor II Blockade Increases IFN-c Expression by
HIV-Specific CD8+ T Cells
We have previously described the presence of suppressor HIV-
specific IL-10 positive CD8+ T cells [2,38]. We hypothesized that
HIV-specific TGF-b positive CD8+ T cells also exert immuno-
suppressive functions [15–18,23,24]. To determine the effect of
TGF-b on the HIV-specific effector functions (as measured by
IFN-c production), PBMC from three HIV-positive volunteers
with evidence of Gag- and Nef-specific TGF-b positive CD8+ T
cells were co-cultured in the presence of anti-TGF-b receptor II
Ab (or isotype control). Blocking of the TGF-b receptor II led to
increased Gag- and Nef-specific IFN-c positive CD8+ T cell
responses (data not shown). These results suggest that TGF-b
production by CD8+ T cells inhibits HIV-specific effector
functions.
Analysis of the Immunophenotypic Profile of HIV-Specific
TGF-b Positive CD8+ T Cells
We have previously shown that the suppressor HIV-specific IL-
10 positive CD8+ T cells were FOXP3 and CD25 negative [2],
and displayed a heterogenous memory phenotype that was distinct
from the HIV-specific effector CD8+ T cell population [38]. In
this study, we examined the immunophenotypic profile of the
HIV-specific TGF-b positive CD8+ T cells. PBMC were
HIV-Specific Ts and CTLA-4
PLoS ONE | www.plosone.org 2 December 2009 | Volume 4 | Issue 12 | e8194stimulated with HIV peptides and the extent of FOXP3, CD25,
CD127, and CD27 expression by the HIV-specific TGF-b positive
CD8+ T cells was assessed. Representative plots are shown in
Fig. 2. HIV-specific TGF-b positive CD8+ T cells were FOXP3
negative and CD25 negative. Similar to the IL-10 positive CD8+
Ts, Gag-specific TGF-b positive CD8+ T cells displayed
heterogeneous expression of CD27 and CD127. In contrast,
HIV-specific IFN-c positive CD8+ T cells were CD27 and CD127
negative (data not shown). These results indicate that the HIV-
specific TGF-b positive CD8+ T cells are different from the
population of suppressor CD8+ T cells in HIV negative
individuals [1,4,11,12,39].
CTLA-4 Blockade Decreases TGF-b and IL-10 Expression
by HIV-Specific CD8+ T Cells
In vitro blockade of CTLA-4 engagement augments HIV-
specific CD4+ T cell proliferation, IL-2, and IFN-c production
[29]. We explored whether this inhibitory mechanism is involved
in HIV-specific TGF-b and IL-10 CD8+ T cells. PBMC from 6
HIV-positive volunteers with demonstrated Gag- and Nef-specific
TGF-b and IL-10 positive CD8+ T cell responses were incubated
with anti-CTLA-4 Ab (or isotype control). Representative plots are
shown in Fig. 3A. CTLA-4 blockade resulted in a significant
decrease in the frequency of HIV-specific TGF-b (Fig. 3C) and IL-
10 (Fig. 3D) positive CD8+ T cell responses. In contrast, blockade
of CTLA-4 led to a significant increase in the frequency of HIV-
specific IFN-c positive CD8+ T cell responses (Fig. 3B). These
results suggest that engagement of CTLA-4 regulates TGF-b and
IL-10 production by HIV-specific CD8+ T cells.
HIV-Specific TGF-b and IL-10 Positive CD8+ T Cells Are
CTLA-4 Negative
CTLA-4 is upregulated in HIV-specific CD4+ T cells [29],
particularly in patients with chronic HIV-1 infection [33]. We next
determined whether CTLA-4 is also expressed on TGF-b and IL-
10 positive CD8+ T cells. Representative plots are shown in Fig. 4.
We found no evidence of CTLA-4 expression on CD8+ T cells,
including TGF-b and IL-10 positive CD8+ T cells (Fig. 4B) as well
as on CD8+ IFN+ T cells (data not shown). This is in contrast to
the high CTLA-4 expression detected on CD4+ T cells (median
Figure 1. TGF-b positive, IL-10 positive, and IFN-c positive HIV-specific CD8+ T cell populations are distinct. PBMC were stimulated
with HIV peptides then stained with anti-IFN-c FITC, anti-TGF-b PE, anti-CD3 AmCyan, anti-CD4 PerCP Cy5.5, and anti-CD8 PE Cy7, anti-IL-10 APC, and
analyzed by flow cytometry. Samples were first gated on the CD3+/CD8+ lymphocyte population then the percent of TGF-b, IFN-c, and IL-10 positive
CD8+ T cells were determined. (A) Data from individuals with significant cytokine expression and analysis were performed by Mann-Whitney U test.
(B) Representative plots of the number of HIV-specific CD8+ T cells expressing TGF-b, IFN-c, and IL-10 after subtraction of the back ground values.
doi:10.1371/journal.pone.0008194.g001
HIV-Specific Ts and CTLA-4
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expression on the CD8+ T cells suggests that the effect of CTLA-4
blockade on the TGF-b and IL-10 positive CD8+ T cells is
mediated by an indirect mechanism.
We next attempted to further elucidate the role of CTLA-4 on
TGF-b and IL-10 production by HIV-specific CD8+ T cells. We
depleted CD4+ T cells in order to examine the effect of CTLA-4
expression by these CD4+ T cells on TGF-b and IL-10
production. Removal of CD4+ T cells fully abrogated the effect
of CTLA-4 blockade on TGF-b, IL-10, and IFN-c production by
HIV-specific CD8+ T cells that we described above (Fig. 5).
Adding back the autologous CD4+ T cells fully restored the effect
of CTLA-4 blockade on TGF-b-, IL-10-, and IFN-c-positive HIV-
specific CD8+ T cells. While a relatively small number of
volunteers were examined in the study, these results strongly
support the role of CTLA-4 positive CD4+ T cells in the
regulation of TGF-b, IL-10, and IFN-c production by HIV-
specific CD8+ T cells.
Discussion
The mechanisms leading to the progressive loss of immune
function and eventual failure of T cell responses in chronic HIV-1
infection remain unresolved. One hypothesis is that effector T cells
succumb to an immunosuppressive environment. Multiple regu-
latory pathways are functionally altered and different CD4+ Treg
subpopulations are induced in different stages of HIV infection
[reviewed in [40]]. Similarly, distinct subpopulations of CD8+ Ts
may also contribute to the immune dysregulation observed in HIV
infection [1,2,4,38]. Suppressor CD8+ T cells produce IL-10 and
TGF-b, and mediate non-antigen specific suppression of T cell
responses [41–43].
Our current study focuses on the mechanisms of suppression
utilized by CD8+ Ts in inhibiting HIV-specific CD8+ T cell
responses.The inhibitionofHIV-specific T-cell responsesby CD8+
Ts has beenattributedto TGF-b and IL-10production [18,38]. We
have previously described the presence of IL-10 positive CD8+ Ts
that inhibited HIV-specific cytolysis and IL-2 production by direct
cell-cell interaction [2], and indirectly by releasing IL-10 [38]. The
presence of these suppressor IL-10 positive CD8+ T cells was
associated with increased expression of the inhibitory receptor
programmed cell death-1(PD-1) on exhausted HIV-specific effector
CD8+ T cells [36]. However, blockade of the PD-1/PDL-1
pathway did not prevent suppression, suggesting that PD-1
engagement is not a mechanism utilized by the IL-10 positive
CD8+ T cells. We now describe an HIV-specific TGF-b positive
CD8+ T cell population that is distinct from IL-10 positive CD8+
Ts. Blocking the binding of TGF-b to its receptor resulted in
increased IFN-c expression by HIV-specific CD8+ T cells. We
postulate that these TGF-b positive CD8+ T cells exert an
inhibitory effect on HIV-specific effector function in vitro.
Nevertheless, the suppressive impact of these TGF-b CD8+ T cells
in vivo remains unknown, and direct cell-cell contact may be
required for the these TGF-b positive CD8+ T cells to exert their
maximum inhibitory effect. The intriguing role by which distinct
antigen-specificity of these TGF-b positive CD8+ T cells contrib-
utes to the level of suppression is remains to be explored [18].
We have previously shown that IL-10 positive CD8+ Ts are
observed in late HIV disease [38]. The induction and detection of
TGF-b positive CD8+ T cells in the course of HIV disease is still
unknown but may develop earlier in HIV disease [44]. Because
TGF-b is a key regulator in the suppressive signaling pathways
implicated in immune regulation, signaling through TGF-b
receptor may promote differential and temporal effect on T cells
in different stages of HIV disease. We have shown previously that
the concomitant presence of Gag- and Nef-specific IL-10 positive
CD8+ Ts augmented the in vitro suppressive effect on effector
CD8+ T cells [38]. We postulate that the concomitant presence of
HIV-specific IL-10 positive and TGF-b positive CD8+ T cells will
promote additive suppression of effector CD8+ T cell responses.
Figure 2. Analysis of regulatory surface markers expression by HIV-specific TGF-b positive CD8+ T cells. PBMC were stimulated with HIV
peptides, then stained for various memory and regulatory markers and the percentage of TGF-b positive CD8+ T cells was determined by flow
cytometry. Samples were first gated on the CD3+/CD8+ lymphocyte population and then the percentages of TGF-b positive cells were determined
and the extent of FOXP3, CD127, CD25, and CD27 expression was also examined. Gating was performed using the fluorescence-minus-one (FMO)
control for each marker. Representative plots of the phenotype of the HIV-specific CD8+ T cells expressing TGF-b. The values marked with an asterisk
represent the fraction of TGF-b positive cells that express FOXP3, CD127, CD25, or CD27 over the total number of TGF-b positive cells (equivalent to
100%).
doi:10.1371/journal.pone.0008194.g002
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T cells with multiple antigen specificities that displayed an
immunophenotype profile that is similar to our previously
described IL-10 positive CD8+ Ts [2]. These TGF-b positive
CD8+ T cells do not display the immunophenotypic patterns
traditionally attributed to regulatory T cells. FOXP3 and CD25
surface expressions are the hallmark for identifying CD8+ Ts in
diseases other than HIV infection [1,3,4,13,14,45–47]. The lack of
CD127 expression on FOXP3 positive CD4+ T cells is used to
distinguish between regulatory and effector T cells [48,49].
However, FOXP3 negative and CD25 negative CD8+ Ts have
also been described [2]. The mechanisms leading to the induction
of these TGF-b positive CD8+ T cells likely share similar pathways
with other regulatory T cells. One key question is whether
CD4+Treg are required for the generation and suppressive
function of CD8+Ts.
Inhibitory functions of regulatory T cells are mediated by
direct binding of CTLA-4 and by cytokine production
[28,50,51]. Surprisingly, engagement of CTLA-4 prevented
the production of suppressive cytokines by the CTLA-4
negative HIV-specific CD8+ T cells. We propose a model by
which CTLA-4 positive CD4+ T cells indirectly influence the
inhibitory function of HIV-specific CD8+ Ts by CTLA-4
engagement. The abrogation of anti-CTLA-4 blockade in the
absence of CD4+ T cells supports our hypothesis. CTLA-4 is
upregulated on HIV-specific CD4+ T cells in advanced disease
[29-31], and CTLA-4 is also constitutively expressed on
regulatory CD4+ Treg [27]. Clearly, the presence of CD4+
Treg in HIV infection adds to the complexity of immune
regulation and suppression. The influence of CTLA-4 expres-
sion by populations other than CD4+ T cells on the
effectiveness of CD8+ suppressor T cells remains to be
determined.
In summary, our study described an HIV-specific CD8+ T cell
population that mediated in vitro suppression of HIV-specific
effector function through the production of TGF-b. These TGF-b
positive CD8+ T cells most likely confer regulatory properties.
Nevertheless, the relative contribution of these TGF-b positive
CD8+ T cells to the general immune dysfunction observed in HIV
infection is currently unknown. The impact of HIV-specific CD8+
Ts remains an intriguing new research area that offers new
direction into the consequence of HIV immunopathogenesis.
Figure 3. CTLA-4 blockade decreases TGF-b and IL-10 expression by HIV-specific CD8+ T Cells. PBMC (n=6) were stimulated with HIV
peptides in the presence of anti-CTLA4 (or isotype control), then stained with anti-IFN-c FITC, anti-TGF-b PE, anti-IL-10 APC, anti-CD3 AmCyan, anti-
CD4 PerCP CY5.5, anti-CD8 PE CY7, and analyzed by flow cytomerty. Samples were first gated on the CD3+/CD8+ lymphocyte population then the
percent of TGF-b, IL-10, and IFN-c positive cells were determined. Results were expressed as percent of HIV-specific CD8+ T cells expressing TGF-b, IL-
10, or IFN-c after subtraction of the back ground. (A) Representative plots of HIV-specific CD8+ T cells expressing TGF-b, IL-10, or IFN-c in the presence
or absence of anti-CTLA-4. (B-D) Dashed line represents the cutoff for significant TGF-b (B), IL-10 (C), and IFN-c (D) expression. Percentages in between
brackets are median values. The two dots joined by a line represent the values obtained from the same individual and analysis was performed by
paired t-test.
doi:10.1371/journal.pone.0008194.g003
HIV-Specific Ts and CTLA-4
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immune regulatory mechanisms modulate the adaptive, antiviral
immune response. The ability to manipulate and regulate effective
antiviral immunity provides an approach toward decreasing the
number of infected cells and improving disease outcome.
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